Last reviewed · How we verify

NCT06583616: PRAGUE-PE

The Prognostic Value of Anion Gap in Predicting Mortality Among Patients With Acute Pulmonary Embolism

Recruiting now Last updated 4 September 2024
What this trial tests

trial testing Anion Gap in Acute Pulmonary Embolism (PE) in 20 participants. Currently enrolling.

Timeline
1 January 2023
Primary endpoint
31 August 2024
30 September 2024

Quick facts

Lead sponsorUniversitas Diponegoro
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20
Start date1 January 2023
Primary completion31 August 2024
Estimated completion30 September 2024
Sites1 location across Indonesia

Drugs / interventions tested

Conditions studied

Sponsor

Universitas Diponegoro — full company profile →

Who can join

Adults 18 to 70, any sex, with Acute Pulmonary Embolism (PE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the prognostic value of the anion gap in predicting mortality among patients with acute pulmonary embolism. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as acute pulmonary embolism by using computed tomography scan (CT scan). The data consist of demographic data, clinical presentation, laboratory, and CT scan were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Universitas Diponegoro trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06583616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing